Stocks & Investing
Stocks and Investing
Stocks and Investing
Tue, January 10, 2023
[ Tue, Jan 10th 2023
] - WOPRAI
[ Tue, Jan 10th 2023
] - WOPRAI
[ Tue, Jan 10th 2023
] - WOPRAI
[ Tue, Jan 10th 2023
] - WOPRAI
[ Tue, Jan 10th 2023
] - WOPRAI
[ Tue, Jan 10th 2023
] - WOPRAI
[ Tue, Jan 10th 2023
] - WOPRAI
[ Tue, Jan 10th 2023
] - WOPRAI
[ Tue, Jan 10th 2023
] - WOPRAI
[ Tue, Jan 10th 2023
] - WOPRAI
[ Tue, Jan 10th 2023
] - WOPRAI
[ Tue, Jan 10th 2023
] - WOPRAI
[ Tue, Jan 10th 2023
] - WOPRAI
[ Tue, Jan 10th 2023
] - WOPRAI
[ Tue, Jan 10th 2023
] - WOPRAI
[ Tue, Jan 10th 2023
] - WOPRAI
[ Tue, Jan 10th 2023
] - WOPRAI
[ Tue, Jan 10th 2023
] - WOPRAI
[ Tue, Jan 10th 2023
] - WOPRAI
[ Tue, Jan 10th 2023
] - WOPRAI
[ Tue, Jan 10th 2023
] - WOPRAI
[ Tue, Jan 10th 2023
] - WOPRAI
[ Tue, Jan 10th 2023
] - WOPRAI
[ Tue, Jan 10th 2023
] - WOPRAI
[ Tue, Jan 10th 2023
] - WOPRAI
[ Tue, Jan 10th 2023
] - WOPRAI
[ Tue, Jan 10th 2023
] - WOPRAI
[ Tue, Jan 10th 2023
] - WOPRAI
[ Tue, Jan 10th 2023
] - WOPRAI
Judah Frommer Maintained (SRPT) at Hold with Increased Target to $114 on, Jan 10th, 2023
Judah Frommer of Credit Suisse, Maintained "Sarepta Therapeutics, Inc." (SRPT) at Hold with Increased Target from $101 to $114 on, Jan 10th, 2023.
Judah has made no other calls on SRPT in the last 4 months.
There are 7 other peers that have a rating on SRPT. Out of the 7 peers that are also analyzing SRPT, 1 agrees with Judah's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Matthew Harrison of "Morgan Stanley" Maintained at Hold with Increased Target to $141 on, Thursday, October 13th, 2022
These are the ratings of the 6 analyists that currently disagree with Judah
- Yun Zhong of "BTIG" Maintained at Strong Buy with Increased Target to $160 on, Thursday, December 22nd, 2022
- Colin Bristow of "UBS" Upgraded from Hold to Strong Buy and Increased Target to $158 on, Friday, December 16th, 2022
- Tazeen Ahmad of "B of A Securities" Maintained at Strong Buy with Increased Target to $138 on, Tuesday, November 29th, 2022
- Brian Abrahams of "RBC Capital" Maintained at Buy with Decreased Target to $190 on, Thursday, November 3rd, 2022
- Salveen Richter of "Goldman Sachs" Maintained at Strong Buy with Increased Target to $171 on, Thursday, November 3rd, 2022
- Joseph Schwartz of "SVB Leerink" Maintained at Buy with Increased Target to $145 on, Monday, October 17th, 2022
